6533b872fe1ef96bd12d3b26
RESEARCH PRODUCT
Intravitreal injection of bevacizumab induces inflammatory alterations in a uveitis experimental model.
Francisco Bosch-morellEmma ArnalAmparo NaveaMaría MuriachSiv Johnsen-sorianoInmaculada AlmansaMaría Sancho-telloFrancisco J. Romerosubject
LipopolysaccharidesMaleVascular Endothelial Growth Factor AChemokinegenetic structuresBevacizumabmedicine.medical_treatmentInflammationAngiogenesis InhibitorsEnzyme-Linked Immunosorbent AssayPharmacologyAntibodies Monoclonal HumanizedAqueous HumorUveitisInterferon-gammaMedicineAnimalsChemokine CCL5Chemokine CCL2biologybusiness.industryAqueous humourGeneral MedicineIntravitreal administrationmedicine.diseaseeye diseasesRatsBevacizumabOphthalmologyDisease Models AnimalCytokineRats Inbred LewMonoclonalIntravitreal Injectionsbiology.proteinCytokinessense organsmedicine.symptombusinessUveitismedicine.drugdescription
PurposeBevacizumab is currently used as an intravitreal agent in the treatment of inflammatory-associated eye diseases. The aim of the current study is to explore the effects of the intravitreal injection of bevacizumab on aqueous humour cytokines and chemokines in an experimental uveitis model.MethodsEndotoxin-induced uveitis was induced in rats by footpad injections. Bevacizumab was administered by intravitreal injection (75 μg in 3–μL samples) and different chemokine and cytokine proteins were quantified in aqueous humor.ResultsIntravitreal administration of bevacizumab led to a several-fold increase of RANTES, MCP-1, and IFN-γ concentrations in aqueous humor of endotoxin-treated rats.ConclusionsGiven the exacerbating effect of bevacizumab on inflammation agents and considering the increasing use of bevacizumab as an off-label intravitreal agent, care should be taken if an underlying inflammatory disease is present.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2010-09-17 | European journal of ophthalmology |